Biogen Idec gains commercial rights of Tysabri from Elan Corporation pharmabiz.com Biogen Idec also has the deepest MS pipeline in the industry with compounds that include PLEGRIDY (peginterferon beta-1a); daclizumab high-yield process (DAC HYP) for monthly subcutaneous administration; and an ongoing study with Tysabri as a ... |
